BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 05, 2011
 |  BC Week In Review  |  Company News  |  Deals

Gilead, Pharmasset deal

Gilead will acquire HCV company Pharmasset for $137 per share in cash. The price is an 89% premium to Pharmasset's close of $72.67 on Nov. 18, before the deal was announced, and values Pharmasset at about $11 billion.

Pharmasset's PSI-7977 is in Phase III testing in combination with ribavirin to...

Read the full 244 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >